Dr. John J. Talley is Co-Founder and Chief Scientific Officer of Euclises Pharmaceuticals, Inc. In addition, John is Co-Founder, Partner, and Vice President of Chemistry at Emmyon, Inc. John is an organic chemist who works to identify targets that can be modulated by chemicals. Currently, the two areas that John is focusing on are developing non-opioid treatments for acute and chronic pain and developing a new medicine that can be used with immune checkpoint inhibitors to slow or reverse tumor growth in cancer. In his free time, John enjoys cultivating vegetables and flowers in his garden, as well as growing indoor plants. Some of his other favorite activities include travel, camping with his family, and playing with his three cats. He received his BA in chemistry and science from Northern Iowa University and his PhD in organic chemistry from the University of Minnesota. Prior to joining the team at Euclises, John worked in various roles at Ironwood Pharmaceuticals, Pharmacia, Searle, Monsanto, and General Electric. John has received numerous honors and awards over the course of his career. He is co-inventor of seven marketed drugs, a named inventor on more than 215 U.S. drug patents, and a recipient of the prestigious PhRMA Foundation Discoverers Award. In our interview, John shares more about his life and research.